A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : Cmax / curve, maximum concentration

[Related PubMed/MEDLINE]
Total Number of Papers: 35
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   Cmax  (>> Co-occurring Abbreviation)
Long Form:   curve, maximum concentration
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Quantification of estradiol cypionate in plasma by liquid chromatography coupled with tandem mass spectrometry: Application in a pharmacokinetic study in healthy female volunteers. MRT
2019 The inhibition mechanism of the uptake of lamivudine via human organic anion transporter 1 by Stellera chamaejasme L. extracts. CMC, MDCK, NCA, NCB, OAT1, SLC22A6
2018 Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects. AUC, COPD, FF, GP, MDI, PK
2017 Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects. ---
2016 Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration. ---
2016 Comparative Physicochemical and Pharmacokinetic Properties of Quetiapine and Its Active Metabolite Norquetiapine. NQTP, QTP
2016 Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. AUC, EQUIGEN, FDA
2016 Pharmacokinetic and pharmacodynamic interactions of aspirin with warfarin in beagle dogs. APTT, CL, INR, IPA, PT
2015 A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents. ATV, AUC, COBI, FDC
10  2015 Pulmonary and Systemic Pharmacokinetics of Colistin Following a Single Dose of Nebulized Colistimethate in Mechanically Ventilated Neonates. CMS
11  2015 The pharmacokinetics of sertraline in overdose and the effect of activated charcoal. BSV, PK, SDAC
12  2014 A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairment. PK, s.c
13  2014 Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies. IRT, PK, Tmax
14  2014 The effect of mild to moderate renal impairment on the pharmacokinetics of the nucleoside analog hepatitis C virus polymerase inhibitor mericitabine. AUC0-12, CI, CLCR, GMR, HCV, NRF
15  2013 Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. AEs, RTG
16  2013 Pharmacokinetics, pharmacodynamics, and safety of esomeprazole injection/infusion in healthy Chinese volunteers: a five-way crossover study. ---
17  2009 Effect of phytomedicines, AM-1, niprisan and nifadin on the pharmacokinetics of chloroquine in rats. AM-1, HPLC, Vd
18  2009 Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. AEs, DPP-4
19  2008 Pharmacokinetics of sertraline across pregnancy and postpartum. MDD, SER, Tmax
20  2007 A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort. AE, AE and EE, EE, SJW
21  2007 Preparation, characterization and in vivo evaluation of ibuprofen binary solid dispersions with poloxamer 188. AUC, DSC, FTIR, SD, SEM, tmax
22  2005 A new Coenzyme Q10 tablet-grade formulation (all-Q) is bioequivalent to Q-Gel and both have better bioavailability properties than Q-SorB. ---
23  2005 Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration. CIs, MR, SR
24  2005 Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol. APTT, ASA
25  1999 Effect of omeprazole on the metabolism of cilostazol. AUCt
26  1999 Effects of CYP3A inhibition on the metabolism of cilostazol. AUCt
27  1999 Effects of taraxacum mongolicum on the bioavailability and disposition of ciprofloxacin in rats. TM
28  1999 Repaglinide pharmacokinetics in healthy young adult and elderly subjects. ---
29  1999 The effect of age on pharmacokinetics of the local anesthetic drug articaine. ---
30  1998 Pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin. Tmax
31  1998 Pharmacokinetics and electrocardiographic effect of ebastine in young versus elderly healthy subjects. ---
32  1997 Pharmacokinetics and pharmacodynamics during treatment with the omeprazole 20 mg enteric-coated tablet and 20 mg capsule in asymptomatic duodenal ulcer patients. tmax
33  1996 Interaction of meloxicam with cimetidine, Maalox, or aspirin. NSAID
34  1996 Serum concentrations of salicylic acid following topically applied salicylate derivatives. ---
35  1987 Pharmacokinetics and pharmacodynamics of two formulations of verapamil. ---